Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endocyte Chooses CEO Successor

Executive Summary

Personalised therapy specialist Endocyte Inc. has appointed Mike Sherman president and CEO succeeding founding CEO Ron Ellis, who has resigned. Sherman has been the company’s chief financial officer since 2006, and took on the additional role of chief operating officer in 2014. Prior to this, he held a variety of executive roles, most recently as vice president of finance and strategic planning at Guidant Corporation.

You may also be interested in...



Coronavirus Update: After UK Nod, New Forecast Makes Pfizer Vaccine The Leader

After its historic first emergency approval, analysts at Bernstein has upgraded predictions for Pfizer/BioNTech's COVID-19 vaccine in 2021 and beyond.

Digital Scrip Awards Celebrate Biopharma After An Exceptional Year

The big winners of the night were AstraZeneca and Roche as pharma, biotech and allied industries came together online on 2 December to celebrate during a ceremony hosted by Ed Balls.

Coronavirus Update: SK Bioscience, Biological E, DongWha And Celltrion Report Progress

SK set for Korean trial with vaccine, as Biological E begins human trials of Baylor vaccine. Meanwhile, DongWha gets a Phase II nod for potential drug, and Celltrion progesses with Phase II regdanvimab trial.

Topics

UsernamePublicRestriction

Register

OM013133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel